14844-73-6Relevant articles and documents
INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
-
Paragraph 00179, (2021/09/04)
Methods of treating polyQ diseases or disorders such as Huntington's Disease are presented. Compounds of formula (I) of the disclosure are capable of binding directly to the polyQ segment of mutated huntingtin. This binding results in at least partial rev
Discovery of carbazole carboxamides as novel RORγt inverse agonists
Huang, Yafei,Yu, Mingcheng,Sun, Nannan,Tang, Ting,Yu, Fazhi,Song, Xiaoxia,Xie, Qiong,Fu, Wei,Shao, Liming,Wang, Yonghui
, p. 465 - 476 (2018/02/28)
A novel series of carbazole carboxamides was discovered as potent RORγt inverse agonists using a scaffold hybridization strategy. Structure-activity relationship exploration on the amide linker, carbazole ring and arylsulfone moiety of the hybrid amide 3a led to identification of potent RORγt inverse agonists. Compound 6c was found to have a good RORγt activity with an IC50 of 58.5 nM in FRET assay, and reasonable inhibitory activity in mouse Th17 cell differentiation assay (58.8% inhibition at 0.3 μM). The binding mode of carbazole carboxamides in RORγt ligand binding domain was discussed.
Design, Synthesis, and Biological Evaluation of Indole Biphenylcarboxylic Acids as PPARγ Antagonists
Asteian, Alice,Blayo, Anne-Laure,He, Yuanjun,Koenig, Marcel,Shin, Youseung,Kuruvilla, Dana S.,Corzo, Cesar A.,Cameron, Michael D.,Lin, Li,Ruiz, Claudia,Khan, Susan,Kumar, Naresh,Busby, Scott,Marciano, David P.,Garcia-Ordonez, Ruben D.,Griffin, Patrick R.,Kamenecka, Theodore M.
, p. 998 - 1003 (2015/09/22)
The thiazolidinediones (TZD) typified by rosiglitazone are the only approved therapeutics targeting PPARγ for the treatment of type-2 diabetes (T2DM). Unfortunately, despite robust insulin sensitizing properties, they are accompanied by a number of severe side effects including congestive heart failure, edema, weight gain, and osteoporosis. We recently identified PPARγ antagonists that bind reversibly with high affinity but do not induce transactivation of the receptor, yet they act as insulin sensitizers in mouse models of diabetes (SR1664).1 This Letter details our synthetic exploration around this novel series of PPARγ antagonists based on an N-biphenylmethylindole scaffold. Structure-activity relationship studies led to the identification of compound 46 as a high affinity PPARγ antagonist that exhibits antidiabetic properties following oral administration in diet-induced obese mice.